Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764554 | 0.84 | MEN1 (0.35) | MEN1POLBKMT2AFAAHMGLL | |
| SCHEMBL9802927 | 0.83 | MGLL (0.42) | MEN1POLBKMT2AFAAHMGLL | |
| SCHEMBL9802715 | 0.79 | HTT (0.36) | MEN1POLBKMT2AHTT | |
| SCHEMBL11052023 | 0.77 | MEN1 (0.53) | MEN1POLBKMT2AFAAHMGLL | |
| SCHEMBL10973154 | 0.77 | FAAH (0.46) | MEN1POLBKMT2AFAAHMGLL | |
| SCHEMBL9803355 | 0.75 | ALDH1A1 (0.40) | MEN1POLBKMT2AMGLLHPGD | |
| SCHEMBL9802993 | 0.72 | KMT2A (0.49) | MEN1POLBKMT2AMGLLTP53 | |
| SCHEMBL4531618 | 0.72 | MEN1 (0.55) | MEN1POLBKMT2AFAAHMGLL | |
| SCHEMBL4390120 | 0.71 | MEN1 (0.44) | MEN1POLBKMT2AFAAHMGLL | |
| SCHEMBL9803298 | 0.71 | CHRM2 (0.35) | MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751116-B1 | Pyrimidine compounds and use thereof in the treatment of central nervous system disorders | ABBOTT GMBH & CO KG (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-8268815-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2361908-A1 | Pyrimidine compounds useful for the treatment of CNS diseases | Abbott GmbH & Co. KG (DE) | 2011-08-31 | — | — | EP | disclosed |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2011-05-19 | — | — | US | disclosed |
| US-7786105-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-07-03 | — | — | US | disclosed |
| EP-1751116-A2 | PYRIMIDINE COMPOUNDS AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118558-A2 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | SLC6A3, GRM3, GPR3 | MEN1 4856/4885POLB 1851/4885KMT2A 4121/4885 |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, MC2R | MEN1 3673/4885POLB 1121/4885KMT2A 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.